Vedolizumab
Vedolizumab
Immunoglobulin G1, anti-(human integrin LPAM-1 (lymphocyte Peyer's patch adhesion molecule 1)) (human-Mus musculus heavy chain), disulfide with human-Mus musculus kappa-chain, dimer
Stoffgruppe
Selektives Immunsuppressivum
Halbwertszeit
25 Tage